摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-(2,5-dideoxy-β-D-threo-pentofuranosyl)adenine | 13116-42-2

中文名称
——
中文别名
——
英文名称
9-(2,5-dideoxy-β-D-threo-pentofuranosyl)adenine
英文别名
(2R,3R,5R)-5-(6-aminopurin-9-yl)-2-methyloxolan-3-ol
9-(2,5-dideoxy-β-D-threo-pentofuranosyl)adenine化学式
CAS
13116-42-2
化学式
C10H13N5O2
mdl
——
分子量
235.246
InChiKey
FFHPXOJTVQDVMO-FSDSQADBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    17
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    99.1
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    2',5'-di-O-(p-toluenesulfonyl)adenosine三乙基硼氢化锂 作用下, 以 四氢呋喃 为溶剂, 反应 16.0h, 以30%的产率得到9-(2,5-dideoxy-β-D-threo-pentofuranosyl)adenine
    参考文献:
    名称:
    在碳水化合物部分甲苯磺酸化的腺嘌呤核苷与三乙基硼氢化锂的反应
    摘要:
    三乙基硼氢化锂与9- / bg-D-D-呋喃核糖基腺嘌呤,9-β-D-阿拉伯呋喃糖基腺嘌呤,9-β-D-木呋喃基腺嘌呤和9的2',3'-二-Op-甲苯基-磺酰基衍生物的反应研究了-β-D-呋喃呋喃糖基腺嘌呤。2′,3′-二-Op-甲苯磺酰腺苷与LiEt 3 BH的反应得到9-(3-脱氧-β-D-戊呋喃糖基)腺嘌呤。该重排反应用于从2',3',5'-三-Op-甲苯磺酰赖氨酸腺苷一步合成9-(3,5-二脱氧-β-D-戊呋喃糖基)腺嘌呤,产率为58%。
    DOI:
    10.1016/s0040-4020(01)89533-8
点击查看最新优质反应信息

文献信息

  • Prodrugs Activated by Rna-Dependent Dna-Polymerases
    申请人:Bertini Ivano
    公开号:US20080300215A1
    公开(公告)日:2008-12-04
    Herein described are prodrugs activated by RNA-dependent DNA-polymerases, such as telomerase and retroviral reverse transcriptases, their use for the treatment of haematological tumours and of blood and blood derivatives from patients affected by retroviral infections, and their use for the preparation of pharmaceutical compositions, to be used for the treatment of solid tumours, of precancerous states and of diseases caused by infection with retroviruses.
    本发明描述了由RNA依赖的DNA聚合酶(如端粒酶和逆转录病毒酶)激活的前药,它们用于治疗血液肿瘤以及受逆转录病毒感染的患者的血液和血液衍生物,并用于制备药物组合物,用于治疗实体肿瘤、癌前状态和由逆转录病毒感染引起的疾病。
  • HERDEWIJN, PIET, TETRAHEDRON, 45,(1989) N0, C. 6563-6580
    作者:HERDEWIJN, PIET
    DOI:——
    日期:——
  • US8110676B2
    申请人:——
    公开号:US8110676B2
    公开(公告)日:2012-02-07
  • US8796241B2
    申请人:——
    公开号:US8796241B2
    公开(公告)日:2014-08-05
  • Reaction of adenine nucleosides, tosylated in the carbohydrate moiety, with lithium triethylborohydride
    作者:Piet Herdewijn
    DOI:10.1016/s0040-4020(01)89533-8
    日期:1989.1
    The reaction of lithium triethylborohydride with the 2′,3′-di-O-p-tolyl-sulphonyl derivatives of 9-/bg-D-ribofuranosyladenine, 9-β-D-arabinofuranosyl-adenine, 9-β-D-xylofuranosyladenine and 9-β-D-lyxofuranosyladenine was studied. The reaction of 2′,3′-di-O-p-tolysulphonyladenosine with LiEt3BH gave 9-(3-deoxy-β-D--pentofuranosyl)adenine. This rearrangement reaction was used for the synthesis of 9-(3
    三乙基硼氢化锂与9- / bg-D-D-呋喃核糖基腺嘌呤,9-β-D-阿拉伯呋喃糖基腺嘌呤,9-β-D-木呋喃基腺嘌呤和9的2',3'-二-Op-甲苯基-磺酰基衍生物的反应研究了-β-D-呋喃呋喃糖基腺嘌呤。2′,3′-二-Op-甲苯磺酰腺苷与LiEt 3 BH的反应得到9-(3-脱氧-β-D-戊呋喃糖基)腺嘌呤。该重排反应用于从2',3',5'-三-Op-甲苯磺酰赖氨酸腺苷一步合成9-(3,5-二脱氧-β-D-戊呋喃糖基)腺嘌呤,产率为58%。
查看更多

同类化合物

鲁西他滨 化合物 T14195 [1,1'-联苯基]-2,3,3',4,4',5'-六醇 [(2R,3R,5S)-3-(氨基甲基)-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]N-[[(2R,3S,5R)-3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]氨基甲酸酯 9-(2-S-苯甲基-5-脱氧-2-硫代五呋喃糖基)-9H-嘌呤-6-胺 5-脱氧胸苷 5-脱氧-5-[(碘乙酰基)氨基]-胸腺嘧啶脱氧核苷 5-碘-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-2,5-二脱氧腺苷酸 5-叠氮基-5-脱氧胸腺嘧啶脱氧核苷 5-三氟乙酰氨基-5-脱氧胸腺嘧啶脱氧核苷 5'-脱氧-5'氟胸苷 5'-脱氧-5'-{[4-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-{[3-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-[4-苯基-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(吡啶-3-基)-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(4-氟苯基)-(1,2,3)三唑-1-基]胸苷 5'-硫代-胸苷3',5'-二乙酸酯 5'-溴乙酰氨基-5'-脱氧胸苷 5'-氨基-5-碘-2',5'-二脱氧尿苷 2-氯-N-[[3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]乙酰胺 2,5-二脱氧腺苷 2',5'-二脱氧尿苷 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]嘧啶-2,4-二酮 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)嘧啶-2,4(1H,3H)-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)-5-碘嘧啶-2,4(1H,3H)-二酮 1-citosin-1-yl-1,2,5-trideoxy-α-L-threo-pentofuranos-4-yloxymethylphosphonic acid 9-[2,5-dideoxy-2-fluoro-5-[N-(N-2-hydroxybenzoyl)sulfamoyl]amino-β-D-ribofuranosyl]adenine triethylammonium salt 5'-amino-2',5'-dideoxy-2'-fuorouridine 1-(5'-deoxythymidin-5'-yl)-4-[methyloxycarbonyl-(2'-deoxy-2',2'-difluorocytidin-4N-yl)]-1H-1,2,3-triazole 2',5'-dideoxy-2'-(3,5-dimethoxybenzamido)-5'-(cyclohexylacetamido)adenosine 2',5'-dideoxy-2'-(3'',5''-dimethoxybenzamido)-5'-(diphenylacetamido)adenosine 2',5'-dideoxy-5'-(hydroxyethylthio)adenosine 1-(5-azido-2,5-dideoxy-2-fluoro-β-D-arabinofuranosyl)-5-ethyluracil 1-(5'-deoxythymidin-5'-yl)-4-[methyl-(2'-deoxy-2',2'-difluorocytidin-4N-yl)]-1H-1,2,3-triazole 4′-C-azidomethyl-2′-deoxy-2′-fluorouridine 2',5'-dideoxy-6-thioguanosine thymidylyl (3'-5') 5'-seleno-5'-deoxythymidine 3'-O-(t-butyldimethylsilyl)-4'-α-methylthymidine (E)- and (Z)-5-(2-bromovinyl)-1-(5-chloro-2,5-dideoxy-β-D-erythro-pentofuranosyl)-5-methyl-4-(1,2,4-triazol-1-yl)pyrimidin-2(1H)-one N-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranos-5-yl>succinamic acid N-butyl-N'-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranose-5-yl>maleamide N-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranos-5-yl>maleamic acid 4'-chloromethyl-2'-deoxy-2',2'-difluorocytidine 4'-chloromethyl-2'-deoxy-2'-fluoro-3'-O-(L-valinyl)cytidine dihydrochloride 5'-deoxy-5'-{4-[2-(3-oxo-3H-benzo[f]chromen-1-yl)acetamidomethyl]-1H-1,2,3-triazol-1-yl}thymidine N6-benzoyl-3'-O-t-butyldimethylsilyl-5'-sulfamoylazido-2',5'-dideoxyadenosine N-{9-[(2R,4S,5R)-5-(Acetylamino-methyl)-4-hydroxy-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide